Teriparatide
Also known as: Forsteo · Teriparatide Sun · Terrosa · Movymia · Livogiva · Sondelbay · Kauliv · Zandoriah · Bonsity · Forteo
General information only. Anpheros does not diagnose and does not recommend treatment. Talk to a doctor or pharmacist about your situation. In an emergency, call 112 (or your local emergency number).
In short
In the European Union, Teriparatide is indicated for the treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture, demonstrating a significant reduction in vertebral and nonvertebral fractures but not hip fractures in postmenopausal women. It is also indicated in the European Union for the treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture. In the United States, Teriparatide is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as having a history of osteoporotic fracture or multiple risk factors, or who have failed or are intolerant to other available osteoporosis therapy. Additionally, in the United States, it is indicated to increase bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture, and to treat men and women with osteoporosis associated with sustained systemic glucocorticoid therapy equivalent to 5 mg or greater of prednisone who are at high risk for fracture or have failed other therapies.
From: Source: European Medicines Agency (EMA), Forsteo — EPAR, 28/01/2026. © European Medicines Agency. · Source: European Medicines Agency (EMA), Teriparatide Sun — EPAR, 10/10/2025. © European Medicines Agency. · Data provided by the U.S. Food and Drug Administration.
AI-generated summary of the sources cited on this page, checked automatically against them. Not reviewed by a clinician; not medical advice.
Codes
- RxNorm
- 32915 teriparatide
- EMA
- EMEA/H/C/000425, EMEA/H/C/005793, EMEA/H/C/003916, EMEA/H/C/004368, EMEA/H/C/005087, EMEA/H/C/005827, EMEA/H/C/004932, EMEA/H/C/006688
Official indications
Quoted unchanged from official product information, in English. Listed alphabetically by product, not ranked.
EMA (EU) Forsteo
Treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture. In postmenopausal women, a significant reduction in the incidence of vertebral and nonvertebral fractures but not hip fractures has been demonstrated. Treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture.
Source: European Medicines Agency (EMA), Forsteo — EPAR, 28/01/2026. © European Medicines Agency.
Document date: 28/01/2026 · Official document →
FDA (USA) Forteo
1 INDICATIONS AND USAGE FORTEO is indicated: For the treatment of postmenopausal women with osteoporosis at high risk for fracture (defined herein as having a history of osteoporotic fracture or multiple risk factors for fracture) or who have failed or are intolerant to other available osteoporosis therapy. In postmenopausal women with osteoporosis, FORTEO reduces the risk of vertebral and nonvertebral fractures. To increase bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture or who have failed or are intolerant to other available osteoporosis therapy. For the treatment of men and women with osteoporosis associated with sustained systemic glucocorticoid therapy (daily dosage equivalent to 5 mg or greater of prednisone) at high risk for fracture or who have failed or are intolerant to other available osteoporosis therapy. FORTEO is a parathyroid hormone analog, (PTH 1-34), indicated for: Treatment of postmenopausal women with osteoporosis at high risk for fracture or patients who have failed or are intolerant to other available osteoporosis therapy ( 1 ) Increase of bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture or patients who have failed or are intolerant to other available osteoporosis therapy ( 1 ) Treatment of men and women with osteoporosis associated with sustained systemic glucocorticoid therapy at high risk for fracture or patients who have failed or are intolerant to other available osteoporosis therapy ( 1 )
Data provided by the U.S. Food and Drug Administration.
Document date: 20260803 · Official document →
EMA (EU) Teriparatide Sun
Teriparatide SUN is indicated in adults. Treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture (see section 5.1). In postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures has been demonstrated. Treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture (see section 5.1).
Source: European Medicines Agency (EMA), Teriparatide Sun — EPAR, 10/10/2025. © European Medicines Agency.
Document date: 10/10/2025 · Official document →
Other treatments A–Z
What people report
Not enough data yet. Anonymous counts appear here only for groups of at least 20 people who agreed to share them.
External resources
Questions
What is Teriparatide approved for in the European Union?
Treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture. In postmenopausal women, a significant reduction in the incidence of vertebral and nonvertebral fractures but not hip fractures has been demonstrated. Treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture. (Source: European Medicines Agency (EMA), Forsteo — EPAR, 28/01/2026. © European Medicines Agency.)
Sources and attribution
- Source: European Medicines Agency (EMA) — EPAR. © European Medicines Agency.
- Data provided by the U.S. Food and Drug Administration.
- Names other than the official source titles: Anpheros translations and plain-language names, made with AI assistance and checked automatically; the source names are in English.
- This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
- Source: European Medicines Agency (EMA), Forsteo — EPAR, 28/01/2026. © European Medicines Agency.
- Source: European Medicines Agency (EMA), Teriparatide Sun — EPAR, 10/10/2025. © European Medicines Agency.
Anpheros Search catalog 2026.10.5, published 17 October 2026. About the data →
About this page. This page brings together public information from official sources, each cited where it is used. It is not medical advice, it is not a diagnosis, and it does not tell you which treatment to take.
Treatments. Indications are quoted unchanged from official product information (European Medicines Agency, U.S. Food and Drug Administration). They describe what a medicine is approved for, not whether it is right for you. Approved uses can differ between countries. Always read the package leaflet and follow your doctor's or pharmacist's advice.
What people report. Figures marked "reported by Anpheros users" are anonymous counts from at least 20 people who agreed to share them. They show what people report, not what works, and they are not clinical evidence.
Links between terms. "May be associated with" means the link appears in a cited source. It does not mean you have that condition.
In an emergency, call 112 (or your local emergency number). Do not delay seeking medical help because of something you read here.